Prediabetes research often focuses on whether an intervention delays type 2 diabetes. A follow-up extending across more than two decades asked a wider question about the accumulation of chronic illness. Prediabetes is often discussed as a warning about future diabetes, but the follow-up looked across a much wider span of health. Decades of records allowed researchers to ask whether an early change in daily habits altered the later accumulation of several diseases at once.
Participants originally assigned to an intensive lifestyle program developed multiple conditions at a lower rate than the placebo group. The benefit belonged to the group originally assigned to the intensive lifestyle program. It does not promise that any single participant will avoid illness, yet it suggests that prevention before diabetes can influence health far beyond a laboratory glucose value.
The analysis followed 1,173 Medicare participants
Researchers examined participants at high risk of diabetes who consented to link trial records with Medicare claims. June 15 NIH research release reports that the original trial ran from 1996 to 1999 and follow-up continued through 2021. Linking the original trial to Medicare claims made the unusually long follow-up possible. The analysis included 1,173 older participants who had consented to the linkage, preserving the randomized assignments from the 1990s while observing diagnoses through 2021. That design is stronger than asking people decades later to remember what they ate or how often they exercised.
Diet, activity and weight goals defined the intervention
The lifestyle group received individual and later group sessions focused on reducing calories and fat, reaching at least 150 minutes of activity each week and losing at least 7 percent of baseline weight. After the initial trial, all groups were offered some lifestyle curriculum, making the long-term difference a conservative comparison of original assignment. The program set concrete targets: at least 150 minutes of activity each week, lower intake of calories and fat, and a loss of at least 7 percent of starting weight. Individual coaching came first, followed by group support. Those components make the intervention more substantial than a brief pamphlet or a single instruction to lose weight.
Risk fell for two-condition and three-condition outcomes
Compared with placebo, original lifestyle assignment was associated with 21 percent lower risk of developing two chronic conditions and 25 percent lower risk of developing three. The analysis covered 15 conditions found in Medicare records, including cardiovascular, kidney, lung, metabolic, musculoskeletal and neurological diagnoses. Researchers counted diagnoses across 15 cardiovascular, kidney, lung, metabolic, musculoskeletal, and neurological conditions. Relative to placebo, the lifestyle assignment was associated with a 21 percent lower risk of developing two chronic conditions and a 25 percent lower risk of developing three. The measure captures disease accumulation, commonly called multimorbidity, rather than one favored diagnosis.
Metformin did not lower multimorbidity risk significantly
Participants originally assigned to metformin did not show a statistically significant reduction in the study’s multiple-condition outcome. That result does not say metformin lacks established uses; it answers the narrower outcome tested in this follow-up. Metformin did not produce a statistically significant reduction in this particular multimorbidity analysis. That finding is not a verdict on every medical use of metformin, nor does it negate earlier evidence about delaying diabetes. It means the long-term claims data did not show the same clear group difference for the multi-condition endpoint examined here.
Most participants eventually had multiple conditions
By the end of follow-up, 85 percent of the linked cohort had at least two chronic conditions. The high overall burden explains why even a relative risk reduction can matter while also showing that the intervention did not eliminate aging-related disease. After the original trial ended, participants in all groups were offered parts of the lifestyle curriculum. That crossover could narrow differences between the original assignments over time, making the observed contrast conservative. Other limitations remain: claims show coded diagnoses and care, not every symptom, behavior change, or biological pathway behind them.
The result supports prevention, not a personal prescription
The study addresses group outcomes from a structured program rather than guaranteeing the same result for every adult with prediabetes. Clinical decisions still depend on health status, ability, medications and professional care, while the trial contributes unusually long evidence about lifestyle assignment. By the end of follow-up, about 85 percent of the cohort had at least two chronic conditions, underscoring how common multimorbidity becomes with age. The practical lesson is not that prevention freezes aging. Early, sustained support for movement, diet, and weight goals may reduce the pace at which several burdens arrive together.
Lifestyle support also differs from asking patients to change alone. The original program supplied coaching, goals, and repeated contact, resources that may be difficult to reproduce in a short medical visit. Translating the finding into routine care therefore involves access, affordability, safe exercise options, and culturally workable food plans. The long follow-up makes prevention look less like a temporary challenge and more like durable health infrastructure: modest changes, supported early, can echo across several diagnoses even when chronic disease remains common in later life.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
